Pure Global
NCT05762094

A Retrospective Study on Personalized Dosing Strategy of Patients Treated by Carbapenems: 2018-2021

A Retrospective Study on Personalized Dosing Strategy of Patients With Bacterial Infections Treated by Carbapenems From a Tertiary Medical Center During 2018-2021
The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School·ClinicalTrials.govRecruiting
View on ClinicalTrials.gov →
Study focus
Disease/Condition
Bacterial Infections
Study type
Observational
Sponsor & location
Primary sponsor
The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School
Location
Nanjing, China
Timeline & enrollment
Phase
N/A
Start date
Mar 01, 2023
End date
Dec 01, 2023
Enrollment
1000 participants
Primary outcome

Mortality,Attainment of Target Trough Concentration

Summary

Patients may benefit from the personalized carbapenem dosing strategy based on
 pharmacokinetics. The objective of this study is to retrospectively review and analyze the
 clinical outcomes of patients with different dosing strategy.

ICD-10 classifications
Bacterial infection, unspecifiedBacterial, viral and other infectious agentsOther bacterial intestinal infectionsOther bacterial diseasesOther specified bacterial intestinal infections
Data source
Registry
ClinicalTrials.gov
Trial ID
NCT05762094
Type
Non-Device Trial
About this record

Access comprehensive clinical trial information for NCT05762094 through Pure Global AI's free database. This phase not specified trial is sponsored by The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School and is currently Recruiting. The study focuses on Bacterial Infections. Target enrollment is 1000 participants.

This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.